Analysts See $0.72 EPS for AMETEK, Inc. (AME); Vistagen Therapeutics (VTGN) Shorts Up By 2.66%

April 23, 2018 - By Ellis Scott

AMETEK, Inc. (NYSE:AME) Logo

Analysts expect AMETEK, Inc. (NYSE:AME) to report $0.72 EPS on May, 2 before the open.They anticipate $0.12 EPS change or 20.00% from last quarter’s $0.6 EPS. AME’s profit would be $166.71M giving it 26.32 P/E if the $0.72 EPS is correct. After having $0.70 EPS previously, AMETEK, Inc.’s analysts see 2.86% EPS growth. The stock decreased 0.94% or $0.72 during the last trading session, reaching $75.81. About 1.35M shares traded or 19.31% up from the average. AMETEK, Inc. (NYSE:AME) has risen 40.32% since April 23, 2017 and is uptrending. It has outperformed by 28.77% the S&P500.

Vistagen Therapeutics Inc (NASDAQ:VTGN) had an increase of 2.66% in short interest. VTGN’s SI was 1.64M shares in April as released by FINRA. Its up 2.66% from 1.59M shares previously. With 600,700 avg volume, 3 days are for Vistagen Therapeutics Inc (NASDAQ:VTGN)’s short sellers to cover VTGN’s short positions. The SI to Vistagen Therapeutics Inc’s float is 18.14%. The stock decreased 13.89% or $0.15 during the last trading session, reaching $0.93. About 1.22M shares traded or 83.19% up from the average. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has declined 48.63% since April 23, 2017 and is downtrending. It has underperformed by 60.18% the S&P500.

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system disorders. The company has market cap of $21.30 million. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder. It currently has negative earnings. It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform to discover, rescue, develop, and commercialize new chemical entities (NCEs) for CNS and other diseases; and regenerative medicine involving hPSC-derived blood, cartilage, heart, and liver cells.

Among 14 analysts covering AMETEK (NYSE:AME), 14 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AMETEK had 63 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was initiated by William Blair on Tuesday, March 22 with “Outperform”. Morgan Stanley maintained the stock with “Overweight” rating in Wednesday, February 7 report. Stifel Nicolaus maintained AMETEK, Inc. (NYSE:AME) on Sunday, December 10 with “Buy” rating. The firm has “Outperform” rating given on Monday, February 8 by RBC Capital Markets. The stock of AMETEK, Inc. (NYSE:AME) has “Buy” rating given on Friday, October 13 by Jefferies. The stock of AMETEK, Inc. (NYSE:AME) has “Outperform” rating given on Thursday, August 3 by BMO Capital Markets. The company was maintained on Friday, August 11 by Cowen & Co. The firm earned “Buy” rating on Friday, October 6 by Robert W. Baird. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, October 11 report. The company was maintained on Friday, September 15 by RBC Capital Markets.

Investors sentiment increased to 1.29 in 2017 Q4. Its up 0.09, from 1.2 in 2017Q3. It improved, as 30 investors sold AMETEK, Inc. shares while 150 reduced holdings. 69 funds opened positions while 163 raised stakes. 192.20 million shares or 0.03% more from 192.13 million shares in 2017Q3 were reported. Moore Mgmt L P holds 0.07% of its portfolio in AMETEK, Inc. (NYSE:AME) for 51,375 shares. 70,570 were reported by Gulf Int Fincl Bank (Uk). Johnson Finance Grp holds 0.04% or 4,214 shares in its portfolio. Eulav Asset Mngmt holds 340,150 shares. Prudential Financial Incorporated, New Jersey-based fund reported 1.28 million shares. Fund owns 11,700 shares. Hanson Mcclain Inc invested 0% of its portfolio in AMETEK, Inc. (NYSE:AME). Ahl Partners Llp reported 76,106 shares stake. Sandy Spring Bank invested in 4,031 shares. Scopus Asset L P reported 0.38% stake. Honeywell International invested 0.97% in AMETEK, Inc. (NYSE:AME). Pennsylvania-based Brinker Cap Incorporated has invested 0.02% in AMETEK, Inc. (NYSE:AME). Walleye Trading Ltd Llc accumulated 6,799 shares or 0% of the stock. 250,714 were accumulated by Gotham Asset Mgmt Lc. Fifth Third Bancorporation accumulated 5,525 shares.

AMETEK, Inc. manufactures electronic instruments and electromechanical devices worldwide. The company has market cap of $17.55 billion. The Company’s Electronic Instruments Group segment offers advanced instruments for the process, power and industrial, and aerospace markets; process and analytical instruments for the oil, gas, petrochemical, pharmaceutical, semiconductor, and automation markets; instruments for the laboratory equipment, ultraprecision manufacturing, medical, and test and measurement markets; and vision systems to inspect surfaces. It has a 25.79 P/E ratio. This segment also provides aircraft and engine sensors, monitoring systems, power instruments, data acquisition units, and fuel and fluid measurement systems for the aerospace industry; power quality monitoring and metering devices, industrial battery chargers, uninterruptible power supplies, programmable power and electrical test equipment, and gas turbine sensors; and dashboard instruments for heavy trucks and other vehicles, as well as timing controls and cooking computers for the food service industry.

Since December 11, 2017, it had 0 buys, and 13 selling transactions for $9.09 million activity. EGINTON WILLIAM D had sold 16,368 shares worth $1.26M on Monday, February 5. $470,375 worth of AMETEK, Inc. (NYSE:AME) was sold by VARET ELIZEBETH R on Wednesday, February 7. Shares for $316,476 were sold by Conti Anthony James on Friday, March 9. Kohlhagen Steven W had sold 3,000 shares worth $229,358 on Wednesday, February 21. Another trade for 25,965 shares valued at $2.04 million was sold by Hardin John Wesley. Another trade for 25,965 shares valued at $1.86M was sold by ZAPICO DAVID A. $1.13M worth of AMETEK, Inc. (NYSE:AME) was sold by Oscher Ronald J.

AMETEK, Inc. (NYSE:AME) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: